283 results on '"Pouessel, D."'
Search Results
2. Pemigatinib for metastatic or surgically unresectable urothelial carcinoma with FGF/FGFR genomic alterations: final results from FIGHT-201
3. Stratégie de préservation vésicale basée sur le traitement trimodal : quelle place dans la prise en charge du carcinome infiltrant de la vessie ?
4. Consolidation nivolumab and ipilimumab versus observation in limited-disease small-cell lung cancer after chemo-radiotherapy – results from the randomised phase II ETOP/IFCT 4-12 STIMULI trial
5. 6 months versus 12 months of adjuvant trastuzumab in early breast cancer (PHARE): final analysis of a multicentre, open-label, phase 3 randomised trial
6. Pemigatinib for Metastatic or Surgically Unresectable Urothelial Carcinoma With FGF/FGFR Genomic Alterations: Final Results From FIGHT-201
7. Clinical and molecular characteristics of non-small-cell lung cancer (NSCLC) harboring EGFR mutation: results of the nationwide French Cooperative Thoracic Intergroup (IFCT) program
8. Tumor heterogeneity of fibroblast growth factor receptor 3 (FGFR3) mutations in invasive bladder cancer: implications for perioperative anti-FGFR3 treatment
9. Guidelines for the definition of time-to-event end points in renal cell cancer clinical trials: results of the DATECAN project
10. EE608 Cost Effectiveness Analysis of a Large (Foundation Medicine) Versus a Home-Based Medium Gene Panel for Exome Sequencing: Results of the Profiler 02 Randomized Clinical Trial
11. Résultats oncologiques des patients présentant une atteinte ganglionnaire à la suite d’une chimiothérapie néoadjuvante et d’une cystectomie totale pour un cancer de la vessie infiltrant le muscle : une étude observationnelle multicentrique du groupe de travail sur le carcinome urothélial de l’eau young academic urologists (YAU)
12. Spécificités cliniques des tumeurs de vessie n’infiltrant pas le muscle métastatique d’emblée : étude observationnelle multicentrique merinos
13. 1762P MERINOS: Metastatic non muscle invasive urothelial carcinoma - An observational study
14. 1757P Preliminary results from AVENANCE, an ongoing, noninterventional real-world, ambispective study of avelumab first-line (1L) maintenance treatment in patients (pts) with locally advanced or metastatic urothelial carcinoma (la/mUC)
15. 1977P Efficacy of talazoparib and avelumab as a maintenance treatment in patients with advanced/metastatic urothelial carcinoma (mUC) whose disease did not progress after a first-line platinum-based chemotherapy (PBCT): The GETUG-TALASUR trial
16. Nouvelles thérapeutiques dans le cancer de la prostate résistant à la castration : panorama des études pivotales et nouveaux schémas thérapeutiques à venir
17. Nouvelles hormonothérapies dans le cancer de la prostate
18. Quelle chimiothérapie périopératoire pour les tumeurs de vessie infiltrant le muscle ?
19. Phase II study of carboplatin and etoposide in patients with anaplastic progressive metastatic castration-resistant prostate cancer (mCRPC) with or without neuroendocrine differentiation: results of the French Genito-Urinary Tumor Group (GETUG) P01 trial
20. Actualités dans le cancer de la prostate lors de l'Asco 2010
21. Stratégies périopératoires dans les carcinomes urothéliaux de vessie infiltrant le muscle
22. Cancers du rein avancés en situations particulières. Comment les traiter?
23. Consolidation nivolumab and ipilimumab versus observation in limited-disease small-cell lung cancer after chemo-radiotherapy – results from the randomised phase II ETOP/IFCT 4-12 STIMULI trial
24. Spécificités de la prise en charge par chimiothérapie chez le sujet âgé
25. 700P Efficacy of sacituzumab govitecan (SG) by trophoblast cell surface antigen 2 (Trop-2) expression in patients (Pts) with metastatic urothelial cancer (mUC)
26. 715P Nivolumab in pretreated metastatic penile squamous cell carcinoma: Results of the penile cohort from the French AcSé prospective program
27. P04.15 Radiomics features in prediction of pseudo-progression and response to hypofractionated stereotactic radiotherapy and anti-PDL1 Durvalumab combination in recurrent glioblastoma from STERIMGLI phase I trial
28. Les effets secondaires de l’hormonothérapie et leur gestion
29. La résistance à la castration: mécanismes physiopathologiques et applications thérapeutiques
30. Séminome de stade I, faut-il enterrer la radiothérapie ?
31. Stratégie de la prise en charge médicale dans les stades métastatiques
32. Création d’une unité de coordination de la prise en charge des tumeurs rares du rein de l’adulte
33. 1062P Anti-PD1 efficacy in European patients with advanced MSI-H/MMRd non-colorectal cancers
34. 2379P AVENANCE: Subgroup analysis of patients (pts) with advanced urothelial carcinoma (aUC) with histological variants from a real-world (RW) study of avelumab first-line maintenance (1LM)
35. 2374P A phase Ib single-arm trial of bintrafusp alfa (BA) for pretreated, locally advanced/unresectable or metastatic (advanced) urothelial cancer (aUC)
36. 2364MO Durvalumab (D) +/- tremelimumab (T) in combination with dose-dense MVAC (ddMVAC) as neoadjuvant treatment in patients with muscle-invasive bladder carcinoma (MIBC): Results of NEMIO, a randomized phase I-II trial
37. 736P Residual masses after salvage chemotherapy in men with metastatic seminoma: The Semi-ResMass multicenter retrospective study
38. Low doses of GM-CSF (molgramostim) and G-CSF (filgrastim) after cyclophosphamide (4 g/m2) enhance the peripheral blood progenitor cell harvest: results of two randomized studies including 120 patients
39. Re: Androgen-Deprivation Therapy Alone or with Docetaxel in Non-Castrate Metastatic Prostate Cancer (GETUG-AFU 15): A Randomised, Open-Label, Phase 3 Trial
40. Cancer du rein
41. Tumeurs germinales du testicule
42. Role of Consolidative Radiotherapy For Metastatic Urothelial Bladder Cancer Patients Without Progression And With No More Than Five Residual Metastatic Lesions Following First Line Systemic Therapy: A Retrospective Analysis
43. Résultats oncologiques des patients ayant des ganglions lymphatiques positifs au moment de la cystectomie radicale avec ou sans chimiothérapie néoadjuvante
44. 526O High activity of nivolumab in patients with pathogenic exonucleasic domain POLE (edPOLE) mutated Mismatch Repair proficient (MMRp) advanced tumours
45. 1059P NEMIO: A randomized phase I-II trial evaluating efficacy and safety of dose dense MVAC (ddMVAC) + durvalumab +/- tremelimumab as neoadjuvant treatment in patients with bladder muscle-invasive urothelial carcinoma
46. LBA24 TROPHY-U-01 cohort 1 final results: A phase II study of sacituzumab govitecan (SG) in metastatic urothelial cancer (mUC) that has progressed after platinum (PLT) and checkpoint inhibitors (CPI)
47. Reversible posterior leukoencephalopathy syndrome after carboplatin therapy
48. NEMIO: A randomized phase II trial evaluating efficacy and safety of dose dense MVAC (ddMVAC) + durvalumab +/- tremelimumab as neoadjuvant treatment in patients with bladder muscle-invasive urothelial carcinoma
49. High level of activity of nivolumab anti-PD-1 immunotherapy and favorable outcome in metastatic/refractory MSI-H non-colorectal cancer: Results of the MSI cohort from the French AcSé program
50. OS4.4 Hypofractionated stereotactic radiotherapy and anti-PDL1 Durvalumab combination in recurrent glioblastoma: Results of the phase I part of the phase I/II STERIMGLI trial
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.